Hair Growth Supplement

Nutrafol Womens Balance Hair Growth Nutraceutical

135 adverse event reports submitted to the FDA · 2023–2025 · Data current as of June 3, 2026

These are reports submitted to the FDA. A report does not mean the product caused the effect. Counts reflect reporting activity, not how common an effect is.

Most Reported Reactions

Top 10 reactions from 135 reports. One report may include multiple reactions — reaction totals may exceed the report count.

Nausea

Diarrhoea

Abdominal pain upper

Hepatic enzyme increased

Hypersensitivity

Palpitations

Abdominal pain

Fatigue

Aspartate aminotransferase increased

Headache

Reported Outcomes

Outcome categories as recorded in FDA reports. One report may include multiple outcomes.

Outcome	Reports
Other Serious or Important Medical Event	120
Hospitalization	46
Visited Emergency Room	38
Visited a Health Care Provider	18
Other Serious Outcome	14
Allergic Reaction	9
Life Threatening	2

Who Reported

Reporter demographics where available. Many reports do not include age or gender data.

Age

Under 18

18–34

35–49

50–64

65–79

80+

Unknown

68 reports had age data; 67 unknown.

Gender

Female

100

Unknown/Not Reported

Reports by Year

Annual report counts from 2023–2025. Spike years may reflect recalls, media coverage, or litigation rather than changes in the product.

'23

'24

'25

Hover bars for exact counts.

Context about this data: Reports concentrated in 2024–2025, reflecting rapid recent market growth of the hair growth supplement category rather than a filing event.

← View all Nutrafol products in FDA data

Data Source

This page presents data from the FDA's CFSAN Adverse Event Reporting System (CAERS) via the openFDA API. Reports are voluntary and unverified. The FDA has not concluded that this product caused any reported event.

View openFDA CAERS data ↗ · About our methodology · How to read this data